ライフサイエンスコーパス: maltophilia

1 Staphylococcus aureus, and Stenotrophomonas maltophilia).

2 zinc L1 beta-lactamase from Stenotrophomonas maltophilia.

3 negative bacilli, including Stenotrophomonas maltophilia.

4 ygenase gene to a megaplasmid in cells of P. maltophilia.

5 d at least one sputum sample positive for S. maltophilia.

6 al microbiology laboratories were in fact S. maltophilia.

7 pportunistic human pathogen Stenotrophomonas maltophilia.

8 Escherichia hermannii, and Stenotrophomonas maltophilia.

9 AmpC-E, CRE, DTR P. aeruginosa, CRAB, and S. maltophilia.

10 AmpC-E, CRE, DTR-P. aeruginosa, CRAB, and S. maltophilia.

11 o-beta-lactamase (MBL) from Stenotrophomonas maltophilia.

12 cASTs) and use CLSI breakpoints (BPs) for S. maltophilia.

13 16S rRNA gene sequencing as Stenotrophomonas maltophilia.

14 acter baumannii (CRAB), and Stenotrophomonas maltophilia.

15 acter baumannii (CRAB), and Stenotrophomonas maltophilia.

16 Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.

17 ug resistant human pathogen Stenotrophomonas maltophilia.

18 reus, A. xylosoxidans, D. acidovorans and S. maltophilia.

19 ident among other respiratory isolates of S. maltophilia.

20 from the emerging pathogen Stenotrophomonas maltophilia.

21 osa and the human pathogen, Stenotrophomonas maltophilia.

22 lin-resistant S. aureus], 2 Stenotrophomonas maltophilia, 1 Klebsiella pneumoniae) and resulted in an

23 terobacter cloacae 1/4; and Stenotrophomonas maltophilia 2/8.

24 and finally, pan-resistant Stenotrophomonas maltophilia (20%).

25 r baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%).

26 erobacter aerogenes (4.4%), Stenotrophomonas maltophilia (4.3%), Proteus mirabilis (4.0%), Klebsiella

27 dans (100%) followed by MDR Stenotrophomonas maltophilia (46%), MDR Achromobacter xylosoxidans (33%),

28 us, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter spp., and Burkholderia spp. d

29 reus, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and atypical myc

30 rkholderia cepacia complex, Stenotrophomonas maltophilia, Acinetobacter baumannii and other rare path

31 552 genomes of the pathogen Stenotrophomonas maltophilia across 23 sites of the lungs from a patient

32 Pseudomonas aeruginosa, and Stenotrophomonas maltophilia--all major threats to our cancer patients.

33 ere, we investigated the pathogenicity of S. maltophilia alone and during polymicrobial infection wit

34 We have now confirmed that S. maltophilia also encodes a type IVA secretion system (Vi

35 the Gram-negative pathogen Stenotrophomonas maltophilia, an important cause of nosocomial infections

36 ring in 2 patients with MDR Stenotrophomonas maltophilia and 2 patients with MDR Achromobacter xyloso

37 To examine the molecular epidemiology of S. maltophilia and A. xylosoxidans in CF, isolates from pat

38 ing can distinguish unique CF isolates of S. maltophilia and A. xylosoxidans, person-to-person transm

39 Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans

40 -negative ESKAPE pathogens, Stenotrophomonas maltophilia and biothreat pathogens.

41 the Gram negative bacteria Stenotrophomonas maltophilia and Escherichia coli.

42 thogen interaction between C. elegans and S. maltophilia and established a new animal model with whic

43 the opportunistic pathogens Stenotrophomonas maltophilia and Ochrobactrum anthropi were detected in m

44 ruginosa, the T4SS promoted the growth of S. maltophilia and reduced the numbers of heterologous bact

45 romobacter xylosoxidans and Stenotrophomonas maltophilia and their antibiotic susceptibility patterns

46 species, Proteus mirabilis, Stenotrophomonas maltophilia ) and Gram-positive bacteria ( Staphylococcu

47 in-resistant P. aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans but was less

48 tobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex were teste

49 rophomonas nitritireducens, Stenotrophomonas maltophilia, and Comamonas testosterone.

50 ae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Enterococcus sp.

51 cies: Cupriavidus gilardii, Stenotrophomonas maltophilia, and Geovibrio thiophilus.

52 Cultures confirmed Stenotrophomonas maltophilia, and oral trimethoprim-sulfamethoxazole (160

53 niae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepacia complex (BCC)

54 epresents the first examination of T2S in S. maltophilia, and the data obtained indicate that Xps T2S

55 While ocular infections caused by S. maltophilia are documented, endogenous endophthalmitis (

56 biology references describe Stenotrophomonas maltophilia as oxidase negative and variable with respec

57 atories should use caution with cASTs for S. maltophilia, as a high rate of errors may be observed.

58 , we present the first documented case of S. maltophilia-associated EE in an immunocompetent adult in

59 S. maltophilia-associated EE is a rare clinical condition,

60 (non-baumannii complex) and Stenotrophomonas maltophilia at this time, and, as such, antimicrobial su

61 S. maltophilia attaches to various mammalian cells, and we

62 ibitors reverse ceftazidime resistance in S. maltophilia because, unlike clavulanic acid, they do not

63 ine (MIN), and ceftazidime (CAZ) with 109 S. maltophilia bloodstream isolates.

64 pp, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, and Acinetobacter bau

65 ve the penetration of antimicrobials into S. maltophilia by conjugating them with TonB substrates wil

66 f CF patients with moderate lung disease, S. maltophilia can be cultured from respiratory tract secre

67 Identification of S. maltophilia can be problematic, and analysis of isolates

68 eruginosa, 14 for A. baumannii, and 2 for S. maltophilia Categorical agreement (CA) was assessed usin

69 Stenotrophomonas maltophilia causes high-mortality infections in immunoco

70 ions in the dinuclear active site of the S. maltophilia Class B3 MbetaL move away from each other, b

71 extensively drug-resistant Stenotrophomonas maltophilia clinical isolate expressing L1.

72 that smlt0009 mutants already exist among S. maltophilia clinical isolates and have reduced susceptib

73 ovel designation within the Stenotrophomonas maltophilia complex associated with isolates derived fro

74 We show that the S. maltophilia complex is divided into 23 monophyletic line

75 stinct component within the Stenotrophomonas maltophilia complex.

76 y transducer TonB, encoded by smlt0009 in S. maltophilia, confer ceftazidime resistance and smlt0009

77 ll cases, the effect of the T4SS required S. maltophilia contact with its target.

78 The extents of S. maltophilia contamination of environmental sites frequen

79 aeruginosa elicited significantly higher S. maltophilia counts in bronchoalveolar lavages and lung t

80 At the six centers with multiple S. maltophilia culture-positive patients and the seven cent

81 xty-one of 69 CF centers screened had 183 S. maltophilia culture-positive patients, and 46 centers ha

82 ients with > or =10 positive cultures (12 S. maltophilia cultures, 15 A. xylosoxidans cultures) had s

83 sequencing for identification and, unlike S. maltophilia, demonstrated susceptibility to most antibio

84 uginosa, the hazard ratio associated with S. maltophilia detection was 0.89 (95% confidence interval,

85 sted their utility to accurately identify S. maltophilia directly from sputum.

86 eruginosa afford a significant benefit to S. maltophilia during polymicrobial infections.

87 of biofilms formed in vitro revealed that S. maltophilia formed well-integrated biofilms with P. aeru

88 ant, opportunistic pathogen Stenotrophomonas maltophilia from 22 countries to infer population struct

89 Recovery of SCV S. maltophilia from the sputum of CF patients has implicati

90 P. aeruginosa, live E. aerogenes, or live S. maltophilia gave good recovery of cysts.

91 acterization of contaminant Stenotrophomonas maltophilia habouring antibiotic resistance genes.

92 maltophilia, those patients positive for S. maltophilia had the following baseline characteristics b

93 the opportunistic pathogen Stenotrophomonas maltophilia has been determined at 1.7 A resolution by t

94 ic sarcosine oxidase (TSOX) from Pseudomonas maltophilia has been determined at 1.85 A resolution.

95 S. maltophilia has been isolated in association with nemato

96 SXT-resistant S. maltophilia has been reported, but the mechanism of resi

97 Background Stenotrophomonas maltophilia has increasingly become a significant hospit

98 Stenotrophomonas maltophilia has plant growth-promoting potential, and in

99 Stenotrophomonas maltophilia has recently emerged as an important nosocom

100 Although patients with CF who acquire S. maltophilia have more advanced disease than those who do

101 epidemiology indicates that patients with S. maltophilia have poorer diagnoses, its clinical signific

102 romobacter xylosoxidans and Stenotrophomonas maltophilia have similar posttransplant survival as comp

103 Nutritional studies of SCV S. maltophilia have suggested auxotrophy in hemin, methioni

104 ative carbapenem use as a risk factor for S. maltophilia in leukemia patients.

105 tility of the SS-PCR to directly identify S. maltophilia in sputum was examined.

106 Pseudomonas aeruginosa and Stenotrophomonas maltophilia increased significantly during the same time

107 Of 90 included patients, 8 (9%) developed S. maltophilia infection (pneumonia, n = 6; skin-soft tissu

108 oral microbiome as a potential source for S. maltophilia infection and highlight cumulative carbapene

109 rs to be important in the pathogenesis of S. maltophilia infection as less than 20% of TNFR1 null mic

110 e bacteremic; and 7/8 (88%) patients with S. maltophilia infection had detectable levels of Stenotrop

111 umulative antibiotic use as predictors of S. maltophilia infection in AML patients receiving remissio

112 No association of S. maltophilia infection with fecal relative abundance was

113 primary outcome, microbiologically proven S. maltophilia infection, was analyzed using a time-varying

114 as the inflammatory response elicited by S. maltophilia infection.

115 Little is known about factors that drive S. maltophilia infection.

116 avity might identify patients at risk for S. maltophilia infection.

117 plus aztreonam as combination therapy for S. maltophilia infections and confirm that aztreonam-like b

118 he optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited.

119 about the treatment of AmpC-E, CRAB, and S. maltophilia infections.

120 acter baumannii (CRAB), and Stenotrophomonas maltophilia infections.

121 s the therapeutic repertoire for managing S. maltophilia infections.

122 allo-beta-lactamase L1 from Stenotrophomonas maltophilia is a dinuclear Zn(II) enzyme that contains a

123 Stenotrophomonas maltophilia is a Gram-negative bacterium found ubiquitou

124 Stenotrophomonas maltophilia is a gram-negative bacterium that has been c

125 Stenotrophomonas maltophilia is a Gram-negative bacterium that is among t

126 Stenotrophomonas maltophilia is a multiple-antibiotic-resistant opportuni

127 Stenotrophomonas maltophilia is a ubiquitous bacterium and an emerging no

128 S. maltophilia is also a risk factor for lung exacerbations

129 Stenotrophomonas maltophilia is an emerging opportunistic and nosocomial

130 Stenotrophomonas maltophilia is an emerging opportunistic pathogen that p

131 Stenotrophomonas maltophilia is an emerging, opportunistic nosocomial pat

132 omated in vitro susceptibility testing of S. maltophilia is challenging because commercial test syste

133 Stenotrophomonas maltophilia is difficult to treat due to the production

134 S. maltophilia is highly resistant to most antibiotics, wit

135 Stenotrophomonas maltophilia is increasingly common in patients with acut

136 The Gram-negative bacterium Stenotrophomonas maltophilia is increasingly identified as a multidrug-re

137 S. maltophilia is increasingly observed in patient sputa in

138 Stenotrophomonas maltophilia is intrinsically resistant to many beta-lact

139 metallo-beta-lactamase from Stenotrophomonas maltophilia is unique among this class of enzymes becaus

140 lass B3 enzyme expressed by Stenotrophomonas maltophilia, is a significant contributor to the beta-la

141 romobacter xylosoxidans and Stenotrophomonas maltophilia, is poorly characterized.

142 ngosepticum isolates, and 1 Stenotrophomonas maltophilia isolate) producing IMP-1, IMP-1-like, IMP-18

143 We found that a local S. maltophilia isolate, JCMS, is more virulent than the oth

144 te, JCMS, is more virulent than the other S. maltophilia isolates (R551-3 and K279a) tested.

145 ulted in amplification of a band from all S. maltophilia isolates and was uniformly negative for all

146 that can rapidly and accurately identify S. maltophilia isolates and which can be used for the direc

147 veloped and tested against a panel of 112 S. maltophilia isolates collected from diverse geographic l

148 A diverse panel of 41 clinical S. maltophilia isolates collected through the SENTRY Antimi

149 s of suspected small-colony-variant (SCV) S. maltophilia isolates from the sputa of five CF patients

150 SCV S. maltophilia isolates were the only S. maltophilia isolates in these cultures, and none were cl

151 Analysis of a collection of 766 S. maltophilia isolates indicated that approximately 20% ar

152 relevant antimicrobials against clinical S. maltophilia isolates nonsusceptible to levofloxacin and/

153 Respiratory and nonrespiratory S. maltophilia isolates were highly immunostimulatory and e

154 The SCV S. maltophilia isolates were the only S. maltophilia isolat

155 The S. maltophilia isolates were weakly invasive, and low-level

156 , as multidrug resistance is common among S. maltophilia isolates, treatment options for these infect

157 baumannii isolates, and 11 Stenotrophomonas maltophilia isolates.

158 i, Serratia marcescens, and Stenotrophomonas maltophilia isolates.

159 ficantly differentially expressed between S. maltophilia JCMS and avirulent bacteria (Escherichia col

160 ken together, these findings suggest that S. maltophilia JCMS evades the pathogen resistance conferre

161 However, S. maltophilia JCMS is virulent to normally pathogen-resist

162 ic bacteria also play a role in combating S. maltophilia JCMS.

163 aride lyase (Smlt1473) from Stenotrophomonas maltophilia k279a, which exhibited significant activity

164 ta-lactam hydrolysis by the Stenotrophomonas maltophilia L1 metallo-beta-lactamase.

165 Furthermore, these results indicate that S. maltophilia may have clinical significance in respirator

166 be P. aeruginosa (n = 10), Stenotrophomonas maltophilia (n = 1), and Burkholderia cepacia (n = 1).

167 as maltophilia (n = 5), MDR Stenotrophomonas maltophilia (n = 26), and CF patients without Achromobac

168 3), Serratia spp. (n = 10), Stenotrophomonas maltophilia (n = 43), Sphingobacterium spp. (n = 3), and

169 omonas aeruginosa (n = 25), Stenotrophomonas maltophilia (n = 46), and Myroides sp. (n = 1).

170 ans (n = 15), pan-resistant Stenotrophomonas maltophilia (n = 5), MDR Stenotrophomonas maltophilia (n

171 n = 3, n = 17), and one of Stenotrophomonas maltophilia (n = 8).

172 who were older than 6 years of age, were S. maltophilia negative in the first year of enrollment, an

173 with live P. aeruginosa, E. aerogenes, or S. maltophilia offer optimal recovery of Acanthamoeba.

174 ndation Registry, to assess the effect of S. maltophilia on survival.

175 Achromobacter xylosoxidans, Stenotrophomonas maltophilia or Bulkholderia cenocepacia (n = 131).

176 on of Burkholderia cepacia, Stenotrophomonas maltophilia, or Alcaligenes xylosoxidans; however, isola

177 nt Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-B-lactamase-producing

178 wn to be highly unstable in Stenotrophomonas maltophilia P21 and Pseudomonas putida H2.

179 aminodeoxychorismate synthase activity of S. maltophilia PabB alone revealed that it is virtually ina

180 ss spectral analysis further suggest that S. maltophilia PabB, like Escherichia coli PabB, binds tryp

181 ies exhibited by StmPr1 may contribute to S. maltophilia pathogenesis in the lung by inducing tissue

182 Xps T2S likely plays an important role in S. maltophilia pathogenesis.

183 o antibiotics may select for both the SCV S. maltophilia phenotype and SXT resistance by interference

184 However, FAD in TSOX from Pseudomonas maltophilia (pTSOX) exhibits properties similar to those

185 st Acinetobacter baumannii, Stenotrophomonas maltophilia, Staphylococcus aureus, Staphylococcus epide

186 Thus, we purified StmPr1 from the S. maltophilia strain K279a culture supernatant and evaluat

187 in the clinically relevant Stenotrophomonas maltophilia strain K279a demonstrates a wide range of pH

188 We recently reported that S. maltophilia strain K279a encodes the Xps type II secreti

189 es of the Xps type II secretion system in S. maltophilia strain K279a.

190 ata from this study, we hypothesized that S. maltophilia strain ZL1 was able to convert E1 to amino a

191 To achieve the objective, Stenotrophomonas maltophilia strain ZL1 was used as a model estrogen degr

192 is a multicomponent enzyme from Pseudomonas maltophilia, strain DI-6, that catalyzes the conversion

193 /D4] T4SS) that is highly conserved among S. maltophilia strains and, looking beyond the Stenotrophom

194 The source of the majority of S. maltophilia strains colonizing the respiratory tracts of

195 confirmed that once established, the SCV S. maltophilia strains persisted.

196 nes xylosoxidans strains, 5 Stenotrophomonas maltophilia strains, and 5 Pseudomonas aeruginosa strain

197 monas aeruginosa strains, 8 Stenotrophomonas maltophilia strains, and 9 isolates belonging to nine ot

198 Pseudomonas maltophilia, Strept, pneumoniae, and P. intermedia were

199 edicated pabA is evident in the genome of S. maltophilia, suggesting that another cellular amidotrans

200 ntain reliable activity against resistant S. maltophilia The role of minocycline in the treatment of

201 Despite the lack of invasiveness of S. maltophilia, the immunostimulatory properties of this or

202 With the exception of Stenotrophomonas maltophilia, these organisms are infrequently implicated

203 Compared with patients without S. maltophilia, those patients positive for S. maltophilia

204 rain K279a, the first clinical isolate of S. maltophilia to be sequenced, encodes a functional type I

205 penemases are restricted to Stenotrophomonas maltophilia, to a few Bacteroides fragilis, and to rare

206 The results of this study indicate that S. maltophilia transiently colonizes the lung accompanied b

207 overall virulence of clinical isolates of S. maltophilia using the well-characterized opportunistic p

208 la, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Vibrio cholerae, and Yersinia enterocolitic

209 Thus, S. maltophilia VirB/D4 T4SS appears to secrete multiple eff

210 oblem, the genetic and molecular basis of S. maltophilia virulence is quite minimally defined.

211 ine in the treatment of infections due to S. maltophilia warrants further clinical investigation give

212 A putative alginate lyase (Smlt1473) from S. maltophilia was heterologously expressed in Escherichia

213 35 home-use nebulizers, and Stenotrophomonas maltophilia was isolated from 4 of 35 home-use nebulizer

214 Stenotrophomonas maltophilia was isolated from the respiratory tracts of

215 e phenotypic switch from wild-type to SCV S. maltophilia was reproducible in vitro by exposure to SXT

216 allo-beta-lactamase L1 from Stenotrophomonas maltophilia was studied using rapid-scan and stopped-flo

217 lues for P. aeruginosa, A. baumannii, and S. maltophilia were 94.1%, 92.7%, and 95.5%, respectively,

218 lues for P. aeruginosa, A. baumannii, and S. maltophilia were 99.5%, 99.2%, and 100%, respectively.

219 lonization, persistence, and virulence of S. maltophilia were assessed in experimental respiratory in

220 Eighty-two isolates of S. maltophilia were cultured from 67 different environmenta

221 The immunostimulatory properties of S. maltophilia were studied in vitro by stimulating airway

222 sence of fungal targets and Stenotrophomonas maltophilia, which were detected in 26 and 4 of 200 spec

223 We compared patients who acquired S. maltophilia with those who did not, using survival analy

224 rcial susceptibility testing systems with S. maltophilia, with a focus on how to implement their use

225 Stenotrophomonas maltophilia WR-C is capable of forming biofilm on polyst

226 sight into the virulence potential of the S. maltophilia Xps type II secretion system and its StmPr1